Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS-136 in the Treatment of Schizophrenia
NCT07521683Phase 2Enrolling by invitation
- Sponsor
- NeuShen Therapeutics
- Start
- Oct 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NS-136 in schizophrenia, sponsored by NeuShen Therapeutics. Started Oct 2025; status: enrolling by invitation.
02
Drugs
NS-136
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07521683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07521683.